ArticleAnnals of medicine2022
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Article in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Risk-Stratified Interventional Management and Surgical Decision-Making in Primary Glaucoma.Biomedicines · 2026Review
- Latanoprost Acid-Brimonidine, a New Amide Prodrug for Glaucoma Management Based on the Concept of Sustained Release.Molecules (Basel, Switzerland) · 2026Article
- Brinzolamide microsponge-loaded in situ gel for sustained ocular delivery: design, characterization and in vivo evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Overview of Intracameral Drug Delivery Systems in Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Advances in loading-release-repair strategies of hydrogels for anterior segment disease therapy.Frontiers in immunology · 2026Review
- Medical and surgical treatment management in open angle glaucoma patients of Asian descent: A narrative review.European journal of ophthalmology · 2025Review
- Epinastine Eyelid Cream as a Practical Option for Patients With Glaucoma on Multidrug Topical Therapy: A Case Report.Cureus · 2025Article
- Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends.BioImpacts : BI · 2025Review
- Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.International journal of nanomedicine · 2025Review
- Nanomedicine in glaucoma treatment; Current challenges and future perspectives.Materials today. Bio · 2024Review
- Review: Neuroprotective Nanocarriers in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Drug Delivery Systems for Glaucoma: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The association between perceived cause of glaucoma and illness perceptions.Frontiers in medicine · 2024Article
- Progress in Ocular Drug Delivery: Challenges and Constraints.Handbook of experimental pharmacology · 2024Article
- Polymer-Based Self-Assembled Drug Delivery Systems for Glaucoma Treatment: Design Strategies and Recent Advances.Polymers · 2023Review
- Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update.Journal of nanobiotechnology · 2023Review
- Recent Advancements in Glaucoma Surgery-A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness. The disease has conventionally been characterized by an elevated intraocular pressure (IOP); however, recent research has built the consensus that glaucoma is not only dependent on IOP but rather represents a multifactorial optic neuropathy. Although many risk factors have been identified ranging from demographics to co-morbidities to ocular structural predispositions, IOP is currently the only modifiable risk factor, most often treated by topical IOP-lowering medications. However, topical hypotensive regimens are prone to non-adherence and are largely inefficient, leading to disease progression in spite of treatment. As a result, several companies are developing sustained release (SR) drug delivery systems as alternatives to topical delivery to potentially overcome these barriers. Currently, Bimatoprost SR (Durysta
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.